Using CGMS, we further identified that young-onset type 2 diabetes, defined as age less than 40-yrs old, received a metformin combination with CSII therapy which required significantly lower insulin doses to maintain glycemic control compared to the late onset diabetes patients [15]. Here, INS is linked to type 2 diabetes mellitus.